Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy-Reference-Cited by-同舟云学术

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy

Published:2018-05-16 Issue:10 Volume:110 Page:1123-1132
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Kurokawa Cheyne¹,Iankov Ianko D¹,Anderson S Keith²,Aderca Ileana¹,Leontovich Alexey A²,Maurer Matthew J²,Oberg Ann L²,Schroeder Mark A³,Giannini Caterina⁴,Greiner Suzanne M⁵,Becker Marc A⁵,Thompson E Aubrey⁶,Haluska Paul⁵,Jentoft Mark E⁴,Parney Ian F⁷,Weroha S John⁵,Jen Jin⁴⁸,Sarkaria Jann N³,Galanis Evanthia¹⁵

Affiliation:

1. Department of Molecular Medicine, Mayo Clinic, Rochester, MN

2. Department of Health Sciences Research, Mayo Clinic, Rochester, MN

3. Department of Radiation Oncology, Mayo Clinic, Rochester, MN

4. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

5. Division of Medical Oncology, Mayo Clinic, Rochester, MN

6. Cancer Biology, Mayo Clinic Florida, Jacksonville, FL, Mayo Clinic, Rochester, MN

7. Department of Neurological Surgery, Mayo Clinic, Rochester, MN

8. Genome Analysis Core, Medical Genome Facility, Mayo Clinic, Rochester, MN

Funder

National Institutes of Health

Richard M. Schulze Family Foundation